Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupranolol SCHEMBL29518497 | 1.00 | L3MBTL1 (0.63) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL34061 | 1.00 | L3MBTL1 (0.63) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL123717 | 1.00 | L3MBTL1 (0.63) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL6508337 | 1.00 | L3MBTL1 (0.63) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL348360 | 0.99 | L3MBTL1 (0.65) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL348362 | 0.99 | L3MBTL1 (0.65) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| SCHEMBL348361 | 0.92 | L3MBTL1 (0.63) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL8908385 | 0.90 | L3MBTL1 (0.53) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL19816741 | 0.89 | LMNA (0.55) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| SCHEMBL12215557 | 0.88 | SLC2A1 (0.57) | L3MBTL1MEN1HTTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716349-B2 | Compositions and methods for the treatment of somatosensory disorders | ALGYNOMICS INC. (US) | 2014-05-06 | — | — | US | claimed |
| US-20130225688-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2013-08-29 | — | — | US | claimed |
| EP-2552433-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | Algynomics Inc. (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011126910-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2011-10-13 | — | — | WO | claimed |
| US-20110245208-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2011-10-06 | — | — | US | claimed |
| US-8716349-B2 | Compositions and methods for the treatment of somatosensory disorders | ALGYNOMICS INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716350-B2 | Compositions and methods for the treatment of somatosensory disorders | ALGYNOMICS INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130225688-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2552433-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | Algynomics Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011126910-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20110245208-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | ALGYNOMICS INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245208-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | OPRL1, OPRD1, OPRK1 | L3MBTL1 1095/4885MEN1 4885/4885HTT 933/4885 |
| US-20130225688-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS | OPRL1, OPRD1, OPRK1 | L3MBTL1 1095/4885MEN1 4885/4885HTT 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.